Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ebiom.2020.102890 http://scihub22266oqcxt.onion/10.1016/j.ebiom.2020.102890 32707445!7372296!32707445     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       EBioMedicine 2020 ; 58 (ä): 102890 Nephropedia Template TP {{tp|p=32707445|t=2020. Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections |pdf=|usr=}}{{32707445}} gab.com Text Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections JO: EBioMedicine http://www.kidney.de/pget.php?&tw=1&pmid=32707445 #FOAvip BACKGROUND: The novel coronavirus (SARS-CoV-2) shares approximately 80% whole genome sequence identity and 66% spike (S) protein identity with that of SARS-CoV. The cross-neutralization between these viruses is currently not well-defined. METHODS: Here, by using the live SARS-CoV-2 virus infection assay as well as HIV-1 based pseudotyped-virus carrying the spike (S) gene of the SARS-CoV-2 (ppSARS-2) and SARS-CoV (ppSARS), we examined whether infections with SARS-CoV and SARS-CoV-2 can induce cross-neutralizing antibodies. FINDINGS: We confirmed that SARS-CoV-2 infects cells via angiotensin converting enzyme 2 (ACE2), the functional receptor for SARS-CoV, and we also found that the recombinant receptor binding domain (RBD) of the S protein of SARS-CoV effectively inhibits ppSARS-2 entry in Huh7.5 cells. However, convalescent sera from SARS-CoV and SARS-CoV-2 patients showed high neutralizing activity only against the homologous virus, with no or limited cross-neutralization activity against the other pseudotyped virus. Similar results were also observed in vaccination studies in mice. INTERPRETATION: Our study demonstrates that although both SARS-CoV and SARS-CoV-2 use ACE2 as a cellular receptor, the neutralization epitopes are not shared by these two closely-related viruses, highlighting challenges towards developing a universal vaccine against SARS-CoV related viruses. FUNDING: This work was supported by the National Key Research and Development Program of China, the National Major Project for Control and Prevention of Infectious Disease in China, and the One Belt and One Road Major Project for infectious diseases. Twit Text FOAVip Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections ????EBioMedicine http://www.kidney.de/pget.php?&tw=1&pmid=32707445 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32707445 #FOAvip English Wikipedia <ref>{{Cite pmid|32707445}}</ref> Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections #MMPMID32707445 Yang R; Lan J; Huang B; A R; Lu M; Wang W; Wang W; Li W; Deng Y; Wong G; Tan W EBioMedicine 2020[Aug]; 58 (ä): 102890 PMID32707445show ga BACKGROUND: The novel coronavirus (SARS-CoV-2) shares approximately 80% whole genome sequence identity and 66% spike (S) protein identity with that of SARS-CoV. The cross-neutralization between these viruses is currently not well-defined. METHODS: Here, by using the live SARS-CoV-2 virus infection assay as well as HIV-1 based pseudotyped-virus carrying the spike (S) gene of the SARS-CoV-2 (ppSARS-2) and SARS-CoV (ppSARS), we examined whether infections with SARS-CoV and SARS-CoV-2 can induce cross-neutralizing antibodies. FINDINGS: We confirmed that SARS-CoV-2 infects cells via angiotensin converting enzyme 2 (ACE2), the functional receptor for SARS-CoV, and we also found that the recombinant receptor binding domain (RBD) of the S protein of SARS-CoV effectively inhibits ppSARS-2 entry in Huh7.5 cells. However, convalescent sera from SARS-CoV and SARS-CoV-2 patients showed high neutralizing activity only against the homologous virus, with no or limited cross-neutralization activity against the other pseudotyped virus. Similar results were also observed in vaccination studies in mice. INTERPRETATION: Our study demonstrates that although both SARS-CoV and SARS-CoV-2 use ACE2 as a cellular receptor, the neutralization epitopes are not shared by these two closely-related viruses, highlighting challenges towards developing a universal vaccine against SARS-CoV related viruses. FUNDING: This work was supported by the National Key Research and Development Program of China, the National Major Project for Control and Prevention of Infectious Disease in China, and the One Belt and One Road Major Project for infectious diseases. |*Cross Reactions[MESH] |Animals[MESH] |Antibodies, Neutralizing/immunology[MESH] |Antibodies, Viral/*immunology[MESH] |Antibody Specificity[MESH] |Betacoronavirus/genetics/*immunology[MESH] |CHO Cells[MESH] |Cell Line, Tumor[MESH] |Cricetinae[MESH] |Cricetulus[MESH] |Female[MESH] |Humans[MESH] |Mice[MESH] |Mice, Inbred BALB C[MESH] |SARS-CoV-2[MESH] |Sequence Homology[MESH] |Severe acute respiratory syndrome-related coronavirus/genetics/*immunology[MESH]Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS(epmc).pdf DeepDyve Pubget Overpricing